Sensory nerves have altered function contralateral to a monoarthritis and may contribute to the symmetrical spread of inflammation.
Rheumatoid arthritis (RA) and rat models of RA exhibit symmetrical mirror-image spread. Many studies have sought to understand the underlying mechanisms and have reported contralateral effects that are manifested in many different forms. It is now well accepted that neurogenic mechanisms contribute to the symmetrical spread of inflammation. However, very few investigators have directly assessed changes in contralateral nerve function and there is a paucity of data. In the present study our aim was to investigate whether there are changes, in particular in the nervous system but also in the vascular system contralateral to an inflamed rat knee joint, that might precede overt inflammation and symmetrical spread. Three to five days following Complete Freund's Adjuvant (CFA) injection we found spontaneous antidromic (away from the CNS) activity in the homologous sensory nerve contralateral to the inflamed joint. Antidromic activity of this nature is known to result in the peripheral release of pro-inflammatory and vasoactive neuropeptides. Importantly, this activity was modulated by systemic analgesic treatment. Furthermore, levels of Evans blue dye extravasation were significantly increased in the joint contralateral to inflammation, indicating altered vascular function. These data suggest that contralateral increases in sensory neural activity and vascular function may account for the symmetrical spread of RA, and that early analgesic treatment may prevent or delay the spread of this debilitating disease.
Kelly
Sara
S
Department of Physiology and Pharmacology, School of Medical Sciences, University of Bristol, Bristol, UK.
Dunham
James Philip
JP
Donaldson
Lucy Frances
LF
D000818:Animals; D001169:Arthritis, Experimental / Q000503:physiopathology*; D002199:Capillary Permeability / Q000187:drug effects; D004396:Coloring Agents; D005070:Evans Blue; D005110:Extracellular Space / Q000502:physiology; D005620:Freund's Adjuvant; D007839:Functional Laterality / Q000502:physiology; D007249:Inflammation / Q000139:chemically induced / Q000503:physiopathology*; D007596:Joints / Q000473:pathology; D008297:Male; D009475:Neurons, Afferent / Q000502:physiology*; D051381:Rats; D017208:Rats, Wistar
D004396:Coloring Agents; D005070:Evans Blue; D005620:Freund's Adjuvant
Brain Res. 1985 Jun 10;336(1):27-31
2408705
Ann Rheum Dis. 1976 Dec;35(6):534-5
1008622
Ann N Y Acad Sci. 1991;632:263-71
1719871
Br J Pharmacol. 1998 Nov;125(6):1304-12
9863661
FEBS Lett. 1996 Jul 22;390(2):165-9
8706851
J Auton Nerv Syst. 1995 Jun 25;53(2-3):205-14
7560757
Rheumatol Int. 1992;12(5):213-6
1290024
Eur J Pharmacol. 1998 Mar 26;345(3):233-45
9592021
Lancet. 1990 Mar 31;335(8692):795
1969540
Br J Rheumatol. 1994 Mar;33(3):249-54
8156287
Arthritis Rheum. 1999 Sep;42(9):1951-60
10513812
Neuron. 1998 Sep;21(3):531-43
9768840
J Physiol. 1986 Oct;379:407-16
2435893
Prog Neurobiol. 2001 Jul;64(4):327-63
11275357
J Neurochem. 2001 Nov;79(4):777-86
11723170
Brain Res. 1995 Aug 7;688(1-2):72-6
8542324
Eur J Neurosci. 1991;3(3):274-284
12106205
J Physiol. 1995 Jul 15;486 ( Pt 2):473-82
7473211
Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3680-5
14990791
Trends Neurosci. 1999 Nov;22(11):495-6
10530993
Neuroreport. 1994 Mar 21;5(7):821-4
8018857
Eur J Pharmacol. 1997 Jul 23;331(2-3):155-60
9274974
Neuroreport. 1997 Sep 8;8(13):2949-52
9376536
Br Med J. 1967 Jul 1;3(5556):26-8
6027379
J Neurosci. 1985 May;5(5):1380-6
3998827
Agents Actions. 1994 Mar;41(1-2):62-70
8079823
J Rheumatol. 1997 Apr;24(4):747-51
9101512
Neuroscience. 1993 Dec;57(4):1091-6
7508583
Neurosci Lett. 1998 Jul 10;250(3):177-80
9708861
Eur J Pain. 2006 Aug;10(6):537-49
16199187
Microvasc Res. 1993 Sep;46(2):143-57
8246815
Brain Res. 1995 Dec 15;704(1):71-8
8750963
J Neurosci. 1986 Dec;6(12):3423-9
3794780
Rheumatology (Oxford). 2003 Nov;42(11):1279-86
12867588
Pharmacol Res. 1989 Jan-Feb;21(1):43-50
2726664
J Neurosci Methods. 1993 Aug;49(1-2):5-10
8271831
J Neurophysiol. 1999 Nov;82(5):2602-11
10561430
J Physiol. 1989 Aug;415:477-86
2640468
Joint Bone Spine. 2005 May;72(3):241-7
15850996
J Neurophysiol. 1996 Dec;76(6):4190-3
8985913
Neuroscience. 1992;47(3):703-12
1584414
J Neurophysiol. 2001 Jul;86(1):49-58
11431487
Brain Res. 2004 Jun 4;1010(1-2):62-8
15126118
Int Immunopharmacol. 2004 Feb;4(2):299-310
14996421
Arthritis Rheum. 1988 Mar;31(3):315-24
3358796
Neuroscience. 2005;134(4):1399-411
16039795
Pain. 2000 Jun;86(3):311-20
10812261
Nature. 1985 Jan 3-9;313(5997):54-6
3917554
Neuroreport. 2004 Jun 28;15(9):1399-403
15194861
J Comp Neurol. 1999 Jan 18;403(3):332-45
9886034
J Rheumatol. 1985 Jun;12(3):406-11
2413204
Int J Clin Pract Suppl. 2002 Jul;(128):2-10
12166614
J Rheumatol. 1995 Aug;22(8):1509-13
7473475
Prostaglandins Leukot Essent Fatty Acids. 1990 Oct;41(2):89-93
2177201
Mol Pharmacol. 2004 Oct;66(4):988-1003
15247320
Gen Pharmacol. 1998 Jan;30(1):5-11
9457475
Br J Rheumatol. 1993 May;32(5):413-6
7684307
Brain Behav Immun. 2004 Nov;18(6):563-71
15331127
Pain. 1983 Jun;16(2):109-10
6877845
Ann Rheum Dis. 1962 Dec;21:370-7
13981183
Neurosci Lett. 1999 Oct 29;274(3):179-82
10548419
Neurosci Lett. 1993 Apr 16;153(1):37-40
8510822
Immunol Cell Biol. 1987 Jun;65 ( Pt 3):267-9
2442097
Exp Brain Res. 1999 Feb;124(4):395-421
10090653
Brain Res. 1999 Jan 23;816(2):598-608
9878885
Microcirculation. 1999 Jun;6(2):83-96
10466111
Brain Res. 1980 Jun 2;191(1):225-37
6247012